236 related articles for article (PubMed ID: 12403563)
1. Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview.
Packer RJ; Rosser T
J Child Neurol; 2002 Aug; 17(8):638-41; discussion 646-51. PubMed ID: 12403563
[TBL] [Abstract][Full Text] [Related]
2. Determination of end points for treatment of neurofibromatosis 1.
Korf BR
J Child Neurol; 2002 Aug; 17(8):642-5; discussion 646-51. PubMed ID: 12403564
[TBL] [Abstract][Full Text] [Related]
3. Plexiform neurofibromas in NF1: toward biologic-based therapy.
Packer RJ; Gutmann DH; Rubenstein A; Viskochil D; Zimmerman RA; Vezina G; Small J; Korf B
Neurology; 2002 May; 58(10):1461-70. PubMed ID: 12041525
[TBL] [Abstract][Full Text] [Related]
4. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC
Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281
[TBL] [Abstract][Full Text] [Related]
5. Plexiform neurofibromas.
Korf BR
Am J Med Genet; 1999 Mar; 89(1):31-7. PubMed ID: 10469434
[TBL] [Abstract][Full Text] [Related]
6. [Progress in diagnosis and treatment of neurofibromatosis in children].
Wang S; Li Y; Zhang J; Ni X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Jun; 36(6):477-482. PubMed ID: 35822370
[No Abstract] [Full Text] [Related]
7. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
[TBL] [Abstract][Full Text] [Related]
8. Is a plexiform neurofibroma pathognomonic of neurofibromatosis type I?
Lin V; Daniel S; Forte V
Laryngoscope; 2004 Aug; 114(8):1410-4. PubMed ID: 15280718
[TBL] [Abstract][Full Text] [Related]
9. [Exclusive nodular plexiform neurofibroma. An unusual case of neurofibromatosis type 1].
Benchikhi H; Zeller J; Wolkenstein P; Wechsler J; Vidaud D; Revuz J
Ann Dermatol Venereol; 1995; 122(9):601-3. PubMed ID: 8745684
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
11. [Management of craniofacial type 1 neurofibromatosis].
Bachelet JT; Combemale P; Devic C; Foray N; Jouanneau E; Breton P
Rev Stomatol Chir Maxillofac Chir Orale; 2015 Sep; 116(4):209-14. PubMed ID: 26194627
[TBL] [Abstract][Full Text] [Related]
12. Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg.
Friedrich RE; Hagel C; Kohlrusch FK; Schanze I; Wieland I; Zenker M
Anticancer Res; 2020 Jun; 40(6):3423-3427. PubMed ID: 32487640
[TBL] [Abstract][Full Text] [Related]
13. Plexiform Neurofibroma With Activating KRAS Mutation and Segmental Presentation Involving the Unilateral Eyelid.
Stallworth JY; Smith LD; Vagefi MR; Pekmezci M
Ophthalmic Plast Reconstr Surg; 2022 Jul-Aug 01; 38(4):e104-e106. PubMed ID: 35797671
[TBL] [Abstract][Full Text] [Related]
14. Giant plexiform neurofibroma in neurofibromatosis type 1.
Savva E; Vargas MI; Beaulieu JY; Truffert A; Burkhardt K; Lobrinus JA; Burkhard PR
Arch Neurol; 2010 Mar; 67(3):356-7. PubMed ID: 20212235
[No Abstract] [Full Text] [Related]
15. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
[TBL] [Abstract][Full Text] [Related]
16. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.
Plotkin SR; Davis SD; Robertson KA; Akshintala S; Allen J; Fisher MJ; Blakeley JO; Widemann BC; Ferner RE; Marcus CL;
Neurology; 2016 Aug; 87(7 Suppl 1):S13-20. PubMed ID: 27527645
[TBL] [Abstract][Full Text] [Related]
17. Severe plexiform facial neurofibromatosis, type 1 with underdeveloped eyes and a novel NF1 mutation.
Kantaputra PN; van den Ouweland A; Sangruchi T; Limwongse C
Am J Med Genet A; 2012 Jul; 158A(7):1750-3. PubMed ID: 22678692
[TBL] [Abstract][Full Text] [Related]
18. Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas.
Poussaint TY; Jaramillo D; Chang Y; Korf B
AJR Am J Roentgenol; 2003 Feb; 180(2):419-23. PubMed ID: 12540445
[TBL] [Abstract][Full Text] [Related]
19. Surgical management of spinal cord compression from plexiform neurofibromas in patients with neurofibromatosis 1.
Pollack IF; Colak A; Fitz C; Wiener E; Moreland M; Mulvihill JJ
Neurosurgery; 1998 Aug; 43(2):248-55; discussion 255-6. PubMed ID: 9696077
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
Ferrer M; Gosline SJC; Stathis M; Zhang X; Guo X; Guha R; Ryman DA; Wallace MR; Kasch-Semenza L; Hao H; Ingersoll R; Mohr D; Thomas C; Verma S; Guinney J; Blakeley JO
Sci Data; 2018 Jun; 5():180106. PubMed ID: 29893754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
